Peripheral Neuropathy Trial, Recruiting (NCT06162403)

Peripheral Neuropathy Trial, Recruiting NCT06162403 Sponsor: M.D. Anderson Cancer Center Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT06162403 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with nerve damage (called CIPN) in their legs or feet lasting 90 days or longer, caused by certain cancer treatments — including specific chemotherapy drugs (vinca alkaloids, taxanes, bortezomib, thalidomide, or platinum-based drugs) or radiation therapy
People who report their pain as 4 or higher on a scale of 0 to 10
People between 18 and 85 years of age
People who finished chemotherapy within the year before joining the trial

Who may not be able to join:

People who have problems with thinking, memory, or understanding
People with a history of drug or alcohol misuse within the past 6 months
People who have an open wound on their skin, or who are currently taking antibiotics for a local or body-wide infection
People who have allergies to local anaesthetics, steroids, or adhesives (such as those used in bandages or patches)
People who have certain health conditions that are considered unsafe for use with the SPRINT PNS System device (confirm with trial site for full details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Saba Javed, MD, M.D. Anderson Cancer Center

Phone: (713) 792-9530

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06162403

Sponsor: M.D. Anderson Cancer Center

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: (713) 792-9530

More information: https://clinicaltrials.gov/study/NCT06162403

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with nerve damage (called CIPN) in their legs or feet lasting 90 days or longer, caused by certain cancer treatments — including specific chemotherapy drugs (vinca alkaloids, taxanes, bortezomib, thalidomide, or platinum-based drugs) or radiation therapy
People who report their pain as 4 or higher on a scale of 0 to 10
People between 18 and 85 years of age
People who finished chemotherapy within the year before joining the trial

Who may not be able to join:

People who have problems with thinking, memory, or understanding
People with a history of drug or alcohol misuse within the past 6 months
People who have an open wound on their skin, or who are currently taking antibiotics for a local or body-wide infection
People who have allergies to local anaesthetics, steroids, or adhesives (such as those used in bandages or patches)
People who have certain health conditions that are considered unsafe for use with the SPRINT PNS System device (confirm with trial site for full details)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

M.D. Anderson Cancer Center

Registry

ClinicalTrials.gov

Start date

22 February 2024

Est. completion

31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov